Feb 9, 2026 08:00AM
Feb 5, 2026 06:30PM
Feb 5, 2026 06:30PM
Jan 14, 2026 08:25PM
Dec 17, 2025 08:00AM
Dec 8, 2025 07:45PM
Dec 8, 2025 07:45PM ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
Dec 8, 2025 07:45PM
Dec 7, 2025 08:10PM
Dec 6, 2025 10:15AM
Dec 4, 2025 07:00PM
Dec 1, 2025 08:00AM
Nov 24, 2025 07:00PM
Nov 19, 2025 08:00AM Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025
Nov 3, 2025 08:10PM
Nov 3, 2025 08:10PM
Aug 17, 2025 07:30PM
Jul 10, 2025 09:30AM
Jul 7, 2025 07:30PM
Jun 15, 2025 07:30PM
Jun 9, 2025 07:30PM Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
Jun 2, 2025 07:30PM
Jun 2, 2025 07:30PM
May 22, 2025 08:15PM
Apr 21, 2025 07:00AM
Mar 25, 2025 07:00PM
Aug 22, 2024 11:34AM
Jun 23, 2024 08:15PM Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares

15,946 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All